Form 4: Exact Sciences Director Sells All Shares Post-Merger

Exact Sciences Director D. Scott Coward reported the disposition of all common stock and stock options following the company's merger with Abbott Laboratories.

Summary

• Director D. Scott Coward reported transactions related to the merger of Exact Sciences Corporation with Abbott Laboratories.
• The merger, effective March 23, 2026, resulted in Exact Sciences becoming a direct, wholly-owned subsidiary of Abbott Laboratories.
• Each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest.
• Coward disposed of 52,164 shares of common stock directly.
• An additional 5,398 shares of common stock, previously subject to vesting, were fully vested, cancelled, and converted into the right to receive the merger consideration.
• 4,694 shares of common stock held indirectly in a 401(k) Plan were also disposed of.
• Stock options to purchase 4,175 shares (exercise price $44.37), 10,786 shares (exercise price $92.62), and 12,875 shares (exercise price $98.18) were cancelled.
• These cancelled options were converted into cash payments equal to the number of shares multiplied by the excess of the $105.00 merger consideration over the respective option's per-share exercise price, less applicable tax withholding.
• Following these transactions, Coward beneficially owns 0 shares of common stock directly and 0 indirectly, and 0 derivative securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for Exact Sciences shareholders and option holders, as the merger consideration provides a definitive cash value, reflecting a successful exit for the company as an independent entity.

Positives

• The merger consideration of $105.00 per share in cash provides a clear and definitive exit value for Exact Sciences shareholders.
• Stock options with exercise prices below the merger consideration were converted into cash payments, allowing option holders to realize value from their equity incentives.

Negatives

• Exact Sciences Corporation is no longer an independent publicly traded entity, becoming a wholly-owned subsidiary of Abbott Laboratories.
• Former shareholders no longer participate in the future growth or potential upside of Exact Sciences as a standalone company.

Future Outlook

This filing does not provide a future outlook for Exact Sciences as it has been acquired and is no longer an independent public entity. Its future outlook is now integrated into Abbott Laboratories' reporting.

Industry Context

StockSavvy.ai notes that the acquisition of Exact Sciences by Abbott Laboratories signifies a consolidation trend in the diagnostics and medical technology sector, where larger players seek to integrate innovative technologies and expand their market presence. This particular transaction highlights the value placed on Exact Sciences' diagnostic capabilities, such as its Cologuard product, by a diversified healthcare giant like Abbott.

Comparison to Industry Standards

• The cash merger consideration of $105.00 per share for Exact Sciences common stock can be compared to recent acquisitions in the diagnostics sector, such as Roche's acquisition of Spark Therapeutics or Danaher's acquisition of Cytiva, though specific valuation multiples would vary based on growth prospects and market share.
• The conversion of in-the-money stock options into cash at the merger consideration minus exercise price is a standard practice in M&A transactions, ensuring that equity incentive holders realize value in line with common industry benchmarks.

Stakeholder Impact

• Shareholders: Received $105.00 cash per share, losing future upside potential as an independent company.
• Employees: Exact Sciences employees are now part of Abbott Laboratories, potentially impacting roles, benefits, and corporate culture.
• Customers: May experience changes in product offerings, support, or branding as Exact Sciences integrates into Abbott.

Next Steps

• No specific future actions for Exact Sciences as an independent entity are mentioned, as it is now a wholly-owned subsidiary of Abbott Laboratories.
• The integration of Exact Sciences' operations and assets into Abbott Laboratories will be the next operational phase.

Key Dates

Keywords

Exact Sciences, EXAS, Abbott Laboratories, Merger, Form 4, Insider Transaction, Stock Options, Common Stock, D. Scott Coward, Acquisition, Cash Consideration